Pancreatic Cancer Research

Clinical trialObsCompleted

Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder

Visceral Lymphatic Mapping Project: A Pilot Study

NCT00489515↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome
Finished, no results posted
Phase
Obs
Status
Completed
Study type
Observational
Start
February 1999
Expected end
August 2010
Enrollment
115 participants
Sites
1
Primary outcomes
Safety, as determined by the number of adverse events resulting from procedure; Ability of surgically defined sentinel lymph nodes to predict whether other lymph nodes are involved with the tumor
Sponsor
Other
Results posted
No
Last update
30 May 2017

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

RATIONALE: Diagnostic procedures, such as visceral lymphatic mapping using isosulfan blue, may help find cancer of the pancreas, colon, stomach, small intestine, or gallbladder and find out how far the disease has spread. PURPOSE: This clinical trial is studying the side effects and how well visceral lymphatic mapping using isosulfan blue works in patients with cancer of the pancreas, colon, stomach, small intestine, or gallbladder.

Detailed description public domain (ClinicalTrials.gov)

OBJECTIVES: Primary * Evaluate the safety and feasibility of visceral lymphatic mapping using isosulfan blue in patients with adenocarcinoma of the pancreas, colon, stomach, small bowel, or gallbladder. * Evaluate the ability of surgically defined sentinel lymph nodes to predict whether other lymph nodes in the basin are involved with the tumor in these patients. Secondary * Compare the results obtained from the sentinel lymph node (i.e., positive or negative for metastatic disease) with the results obtained from the other nodes in these patients. * Compare immunohistochemical analysis with standard analysis of the sentinel lymph nodes in these patients. * Evaluate the value of intraoperative touch prep analysis of sentinel lymph nodes in these patients. OUTLINE: This is a pilot study. During surgical resection of the primary tumor, patients receive isosulfan blue subcutaneously 5 minutes before undergoing sentinel lymph node identification/excision and radical lymphadenectomy. Tissue samples are analyzed by IHC for cytokeratins and CEA.

Papers 4

The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.